Search Result

Results for "

cerebral level

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Amyloid-β (3) Apoptosis (4) ATP Synthase (2) Biochemical Assay Reagents (1) Calcium Channel (1) Dopamine Receptor (2) Dopamine Transporter (1) Drug Intermediate (1) Endogenous Metabolite (4) Glutaminase (1) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) IKK (1) Isotope-Labeled Compounds (1) Monoamine Transporter (1) NF-κB (3) NO Synthase (1) Nucleoside Antimetabolite/Analog (1) P2Y Receptor (2) Reactive Oxygen Species (ROS) (1) Reference Standards (4) TMV (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (2) Endocrinology (1) Infection (1) Inflammation/Immunology (4) Metabolic Disease (2) Neurological Disease (16)

By Targets:

Adrenergic Receptor (1)

Amyloid-β (3)

Apoptosis (4)

ATP Synthase (2)

Biochemical Assay Reagents (1)

Calcium Channel (1)

Dopamine Receptor (2)

Dopamine Transporter (1)

Drug Intermediate (1)

Endogenous Metabolite (4)

Glutaminase (1)

HDAC (1)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Methyltransferase (1)

IKK (1)

Isotope-Labeled Compounds (1)

Monoamine Transporter (1)

NF-κB (3)

NO Synthase (1)

Nucleoside Antimetabolite/Analog (1)

P2Y Receptor (2)

Reactive Oxygen Species (ROS) (1)

Reference Standards (4)

TMV (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (2)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (4)

Metabolic Disease (2)

Neurological Disease (16)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0045

Ginsenoside Rg1 Maximum Cited Publications 12 Publications Verification Panaxoside A; Panaxoside Rg1	Amyloid-β NF-κB Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Ginsenoside Rg1 is one of the major active components of Panax ginseng. Ginsenoside Rg1 ameliorates the impaired cognitive function, displays promising effects by reducing cerebral Aβ levels. Ginsenoside Rg1 also reduces NF-κB nuclear translocation.

HY-122218

JHU-083 5+ Cited Publications	Glutaminase	Neurological Disease
JHU-083, a proagent of 6-diazo-5-oxo-L-norleucine (DON; HY-108357), is an orally active and selective glutaminase antagonist. JHU-083 blocks glutaminase activity in brain CD11b ⁺ cells and experimental cerebral malaria (ECM) resulting in a net decrease of glutamate levels in the animals .

HY-B0158R

Cytidine (Standard) Cytosine β-D-riboside (Standard); Cytosine-1-β-D-ribofuranoside (Standard)	Reference Standards Nucleoside Antimetabolite/Analog Endogenous Metabolite	Neurological Disease
Cytidine (Standard) is the analytical standard of Cytidine. This product is intended for research and analytical applications. Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function . In Vivo:Cytidine decreases glutamate/glutamine levels and induces earlier improvement of depressive symptoms .

HY-118570

5-Oxoprolyltryptophan	Biochemical Assay Reagents	Neurological Disease
5-Oxoprolyltryptophan is a model substrate for investigating the increase of serotonin at the cerebral level .

HY-176347S

Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2	Isotope-Labeled Compounds	Cancer
Alpha Feto Protein, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled Alpha Feto Protein.

HY-116062

JNJ-7925476 hydrochloride	Monoamine Transporter Dopamine Transporter Adrenergic Receptor	Others
JNJ-7925476 (hydrochloride) is a triple monoamine uptake inhibitor with the ability to regulate neurotransmitter levels and antidepressant activity. JNJ-7925476 (hydrochloride) can be rapidly absorbed into the plasma in rats, with a higher concentration in the brain than in plasma. It can induce an increase in the levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibits antidepressant activity in the mouse tail suspension test.

HY-N12249

7-Deoxy-trans-dihydronarciclasine	Amyloid-β TMV	Infection Neurological Disease Inflammation/Immunology
7-Deoxy-trans-dihydronarciclasine, an alkaloid, is a tobacco mosaic virus (TMV) inhibitor (IC₅₀: 1.80 μM). 7-Deoxy-trans-dihydronarciclasine is an anti-neuroinflammatory agent. 7-Deoxy-trans-dihydronarciclasine decreases the Aβ and APP levels in the cerebral cortex of Tg2576 mice .

HY-W087952R

(R)-(-)-2-Butanol (Standard)	Drug Intermediate Reference Standards	Endocrinology
Ginsenoside Rg1 (Standard) is the analytical standard of Ginsenoside Rg1. This product is intended for research and analytical applications. Ginsenoside Rg1 is one of the major active components of Panax ginseng. Ginsenoside Rg1 ameliorates the impaired cognitive function, displays promising effects by reducing cerebral Aβ levels. Ginsenoside Rg1 also reduces NF-κB nuclear translocation.

HY-N0045R

Ginsenoside Rg1 (Standard) Panaxoside A (Standard); Panaxoside Rg1 (Standard)	Reference Standards Amyloid-β NF-κB Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Ginsenoside Rg1 (Standard) is the analytical standard of Ginsenoside Rg1. This product is intended for research and analytical applications. Ginsenoside Rg1 is one of the major active components of Panax ginseng. Ginsenoside Rg1 ameliorates the impaired cognitive function, displays promising effects by reducing cerebral Aβ levels. Ginsenoside Rg1 also reduces NF-κB nuclear translocation.

HY-111066

JNJ-37822681	Dopamine Receptor	Others
JNJ-37822681 is a fast dissociating D2 antagonist with activity in inhibiting schizophrenia. JNJ-37822681 has high specificity for D2 receptors and is effective in animal models, inducing increased levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibiting antidepressant activity in the mouse tail suspension test, while having a good brain distribution and lower prolactin release.

HY-174127

P2Y1 antagonist 3	P2Y Receptor	Neurological Disease
P2Y1 antagonist 3 (compound 36b) is a blood-brain barrier (BBB)-penetrant P2Y1 antagonist with an IC₅₀ of 0.50 μM. P2Y1 antagonist 3 exhibits protective effects in a rat middle cerebral artery occlusion (MCAO) model and demonstrates neuroprotective activity against oxidative stress by upregulating nuclear Nrf2 protein levels .

HY-113126A

3-Hydroxyisobutyric acid sodium	Endogenous Metabolite ATP Synthase	Neurological Disease Metabolic Disease
3-Hydroxyisobutyric acid sodium is an intermediate in the metabolic pathways of L-valine and thymine, and can be found in urine. 3-Hydroxyisobutyric acid sodium is a secreted mediator of endothelial cell fatty acid transport and insulin resistance. 3-Hydroxyisobutyric acid sodium can also inhibit key enzymes of energy metabolism in the cerebral cortex of young rats. The levels of 3-Hydroxyisobutyric acid sodium are closely related to various diseases such as 3-hydroxyisobutyric aciduria, diabetes, and ketoacidosis .

HY-113126

3-Hydroxyisobutyric acid	Endogenous Metabolite ATP Synthase	Neurological Disease Metabolic Disease
3-Hydroxyisobutyric acid is an intermediate in the metabolic pathways of L-valine and thymine, and can be found in urine. 3-Hydroxyisobutyric acid is a secreted mediator of endothelial cell fatty acid transport and insulin resistance. 3-Hydroxyisobutyric acid can also inhibit key enzymes of energy metabolism in the cerebral cortex of young rats. The levels of 3-Hydroxyisobutyric acid are closely related to various diseases such as 3-hydroxyisobutyric aciduria, diabetes, and ketoacidosis .

HY-W116433

SK609	Dopamine Receptor	Neurological Disease
SK609 is a selective dopamine D3 receptor agonist with activity that improves dopamine and norepinephrine levels in the cerebral cortex. SK609 has been successfully used to suppress dyskinesias in Parkinson's disease models and alleviated muscle twitches induced by L-dopa. SK609 improved performance in sustained attention tasks by significantly reducing misses and false alarms. SK609 may provide an inhibitory option for suppressing movement and cognitive impairment in patients with Parkinson's disease .

HY-107661

Arundic Acid 2 Publications Verification ONO-2506; (R)-2-Propyloctanoic acid	Others	Neurological Disease
Arundic acid (ONO-2506) is an astrocyte-modulating agent, which delays the expansion of cerebral infarcts by modulating the activation of astrocytes through inhibition of S-100β synthesis. Arundic acid also increases the expression level of EAAT1 by activating the Akt, ERK, and NF-κB signaling pathways, which has the potential to eliminate excess glutamate and inhibit excitotoxic brain damage or death. Arundic acid has the potential for stroke and Alzheimer’s disease research .

HY-146351

HDAC-IN-38	HDAC	Neurological Disease
HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDAC1, 2, 3, 5, 6, and 8. HDAC-IN-38 increases cerebral blood flow (CBF), attenuates cognitive impairment, and improves hippocampal atrophy. HDAC-IN-38 also increases the level of histone acetylation (H3K14 or H4K5) .

HY-168096

iNOs-IN-5	NO Synthase Apoptosis	Cardiovascular Disease Neurological Disease
iNOs-IN-5 (Compound BN-4) is an inhibitor for iNOS with an IC₅₀ of 0.1707 μM, and reduces NO levels in LPS (HT-D1056)-induced RAW264.7 cells. iNOs-IN-5 reduces the hypoxic injury stimulated ROS and lactate dehydrogenase expression, and exhibits anti-necrosis and anti-apoptosis efficacy. iNOs-IN-5 exhibits anti-cerebral ischemia and neuroprotective activities in SD rat models. iNOs-IN-5 is blood-brain barrier penetrable .

HY-120985

Araguspongin B	Calcium Channel	Neurological Disease
Xestospongins and araguspongins are marine natural products first isolated from Pacific basin sponges, and noted to have vasodilatory properties.1 Inositol phosphates (IP) are important signal transduction messengers acting via IP3 receptors to promote the mobilization of Ca2+ from intracellular stores.2 Araguspongin B antagonizes the calcium-releasing action of inositol 1,4,5-trisphosphate at the receptor level in cerebral microsomes, with an IC₅₀ of 0.6 μM. It is nearly as potent as xestospongin C as an antagonist of the IP3 receptor.

HY-175521

HIF-1α-IN-8	HIF/HIF Prolyl-Hydroxylase IKK NF-κB Apoptosis Reactive Oxygen Species (ROS)	Inflammation/Immunology
HIF-1α-IN-8 is an orally active HIF-1α inhibitor, with an IC₅₀ of 2.02 μM. HIF-1α-IN-8 significantly suppresses the expression of inflammation factors of IL-6 and NO, reduces hypoxia-induced ROS production and apoptosis in C8-D1A cells. HIF-1α-IN-8 inhibits HIF-1α/IKKα/NF-κB signaling pathway and reduces the expression of blood-brain barrier permeability-related proteins. HIF-1α-IN-8 reduces brain water content and oxidative stress level in mice with high altitude cerebral edema (HACE) model. HIF-1α-IN-8 can be used for the study of high altitude cerebral edema (HACE) .

HY-174126

P2Y1 antagonist 2	P2Y Receptor	Cardiovascular Disease
P2Y1 antagonist 2 (Compound 19) is a P2Y1 receptor antagonist (IC₅₀: 0.49 μM). P2Y1 antagonist 2 has significant antiplatelet aggregation activity and exerts its effects by inhibiting P2Y1 receptor. P2Y1 antagonist 2 can upregulate nuclear Nrf2 protein levels, exhibit neuroprotective effects, and resist oxidative stress damage. P2Y1 antagonist 2 can effectively reduce cerebral infarction area and improve neurobehavioral function, and can be used in the study of ischemic stroke .

HY-116062A

JNJ-7925476	Histone Methyltransferase	Neurological Disease
JNJ-7925476 is a triple reuptake inhibitor that selectively and potently inhibits the activity of the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT). JNJ-7925476 is rapidly absorbed into the blood and its concentration in the brain is 7-fold higher than that in plasma. The occupancy ED(50) values of JNJ-7925476 for SERT, NET, and DAT in the rat brain are 0.18, 0.09, and 2.4 mg/kg, respectively. JNJ-7925476 rapidly induces a significant increase in the levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex in a dose-dependent manner. JNJ-7925476 exhibits potent antidepressant-like activity in the mouse tail suspension test. These results suggest that JNJ-7925476 has in vivo efficacy in biochemical and behavioral models of depression .

HY-B2167R

Docosahexaenoic acid (Standard) DHA (Standard); Cervonic acid (Standard)	Reference Standards Endogenous Metabolite	Neurological Disease Cancer
Docosahexaenoic acid (Standard) is the analytical standard of Docosahexaenoic acid. This product is intended for research and analytical applications. Docosahexaenoic Acid (DHA) is an omega-3 fatty acid abundantly present brain and retina. It can be obtained directly from fish oil and maternal milk. In Vitro: Docosahexaenoic acid (DHA) is essential for the growth and functional development of the brain in infants. DHA is also required for maintenance of normal brain function in adults. The inclusion of plentiful DHA in the diet improves learning ability and memory . DHA is an essential requirement in every step of brain development like neural cell proliferation, migration, differentiation, synaptogenesis. The multiple double bonds and unique structure allow DHA to impart special membrane characteristics for effective cell signaling. Many development disorders like dyslexia, autism spectrum disorder, attention deficit hyperactivity disorder, schizophrenia etc. are causally related to decreased level of DHA . DHA is a potent RXR ligand inducing robust RXR activation already at low micro molar concentrations. The EC₅₀ for RXRα activation by DHA is about 5-10 μM fatty acid . In Vivo: Docosahexaenoic acid administration over 10 weeks significantly reduces the number of reference memory errors, without affecting the number of working memory errors, and significantly increases the docosahexaenoic acid content and the docosahexaenoic acid/arachidonic acid ratio in both the hippocampus and the cerebral cortex . DHA treatment exerts neuroprotective actions on an experimental mouse model of PD. There is a decrease tendency in brain lipid oxidation of MPTP mice but it does not significantly .

Cat. No.	Product Name	Category	Target	Chemical Structure